Rapid Micro Biosystems, Inc. cash flow statement
In fiscal 2025, Rapid Micro Biosystems, Inc.'s operations generated −$31.1m of cash; it spent $850,000 on capital projects, leaving free cash flow of −$31.9m.
Cash flow statement
| Fiscal year | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMJun 2026 |
|---|---|---|---|---|---|---|---|
| Cash from operations | −31 | −55 | −59 | −45 | −44 | −31 | −40 |
| Depreciation and amortisation | 2 | 2 | 3 | 3 | 3 | 3 | 3 |
| Stock-based pay | 1 | 2 | 4 | 5 | 4 | 4 | 4 |
| Capital spending | 1 | 3 | 7 | 2 | 1 | 1 | 0 |
| Free cash flow | −32 | −58 | −65 | −47 | −46 | −32 | −40 |
| Free cash flow after stock pay | −32 | −60 | −69 | −52 | −49 | −36 | −45 |
| Shares issued | — | — | — | — | 0 | 0 | — |
| Quarter | 2024 Q3Sept 2024 | 2024 Q4Dec 2024 | 2025 Q1Mar 2025 | 2025 Q2Jun 2025 | 2025 Q3Sept 2025 | 2025 Q4Dec 2025 | 2026 Q1Mar 2026 | 2026 Q2Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | −9 | −10 | −9 | −10 | −9 | −3 | −15 | −13 |
| Depreciation and amortisation | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Stock-based pay | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Capital spending | 0 | 0 | 0 | 0 | 0 | 0 | 0 | −0 |
| Free cash flow | −9 | −10 | −9 | −10 | −9 | −3 | −15 | −12 |
| Free cash flow after stock pay | −10 | −11 | −10 | −11 | −10 | −4 | −17 | −14 |
Compare with peers
- Maxcyte, Inc. cash flow
- Omniab, Inc. cash flow
- Bionano Genomics, Inc. cash flow
- Alpha Teknova, Inc. cash flow
- Champions Oncology, Inc. cash flow
Head to head: MXCT vs RPIDOABI vs RPIDBNGO vs RPIDRPID vs TKNO
More: Life Sciences Tools & Services stocks compared, Health Care sector, rankings of US companies